EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Antibody Response to SARS-CoV-2 before and after the Third Vaccination in Patients with Inflammatory Bowel Disease

Johanna Maria Classen, Anna Muzalyova, Christoph Römmele, Sandra Nagl, Alanna Ebigbo, Elisabeth Schnoy

Digestive Diseases · 2024

DOI: 10.1159/000542353 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Digestive Diseases, 2024. Verfasst von Johanna Maria Classen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine III, University Hospital Augsburg, Augsburg, Germany. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, COVID-19, SARS-CoV-2, Antibodies, Viral. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Patients with inflammatory bowel disease (IBD) receiving immunosuppressive therapy might have an increased risk of developing a severe course of SARS-CoV-2 infection. The aim of this study was to investigate the development of antibodies in immunosuppressed patients with IBD compared to a healthy control group and to determine the effect of immunomodulators on the level of anti-SARS-CoV-2 IgG antibody levels before and after a third vaccination against SARS-CoV-2.

Methods

This is a single-center study with a retrospective observational design. Seventy-one IBD patients matched by propensity score to 71 healthy employees (control group) were included. Blood was taken from both groups at predetermined times before and after the third booster vaccination.

Results

All patients with IBD (n = 71, 100%) received immunomodulatory therapy. The mean antibody level before the third vaccination was 1,352.88 U/mL (SD = 1,011.489) in the IBD group and was not lower compared to the control group (p = 0.088). Gender, age, and disease duration had no significant impact on the development of antibody levels. Patients with TNF-alpha blockers had significantly lower antibody titers (p = 0.011) compared to the control group. Patients with integrin inhibitor therapy had significantly higher antibody titers (p = 0.003) than the controls. After the third vaccination, an increase in antibody titers was recorded in all patients in the IBD group.

Conclusion

We recorded an antibody titer in all patients with IBD that was not significantly lower compared to healthy controls despite immunomodulatory therapy. The booster vaccination led to an increase in antibody levels in all patients with IBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesCOVID-19SARS-CoV-2Antibodies, ViralCOVID-19 VaccinesAntibody FormationHumansMaleFemaleAdultMiddle AgedRetrospective StudiesImmunosuppressive AgentsImmunization, SecondaryImmunocompromised HostImmunoglobulin G

Stichwörter der Autor:innen

Booster vaccinationCrohn’s diseaseInflammatory bowel diseaseSARS-CoV-2Ulcerative colitisVaccination

Substanzen

Antibodies, ViralCOVID-19 VaccinesImmunosuppressive AgentsImmunoglobulin G

Autor:innen und Institutionen

  • Internal Medicine III, University Hospital Augsburg, Augsburg, Germany.
  • Internal Medicine III, University Hospital Augsburg, Augsburg, Germany, elisabeth.schnoy@uk-augsburg.de.

Zitieren

APA

Classen, J. M., Muzalyova, A., Römmele, C., Nagl, S., Ebigbo, A., & Schnoy, E. (2024). Antibody Response to SARS-CoV-2 before and after the Third Vaccination in Patients with Inflammatory Bowel Disease. Digestive Diseases. https://doi.org/10.1159/000542353

Vancouver

Classen JM, Muzalyova A, Römmele C, Nagl S, Ebigbo A, Schnoy E. Antibody Response to SARS-CoV-2 before and after the Third Vaccination in Patients with Inflammatory Bowel Disease. Digestive Diseases. 2024. doi:10.1159/000542353

BibTeX
@article{Classen2024,
  author = {Classen, Johanna Maria and Muzalyova, Anna and Römmele, Christoph and Nagl, Sandra and Ebigbo, Alanna and Schnoy, Elisabeth},
  title = {Antibody Response to SARS-CoV-2 before and after the Third Vaccination in Patients with Inflammatory Bowel Disease},
  journal = {Digestive Diseases},
  year = {2024},
  doi = {10.1159/000542353}
}
Kostenlos starten →